STEPHEN LOUGHRAN: Open Payments
NPI 1801865308 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,184 in 46 payments from 18 companies in 2025. Trend: 2023 $1,469 · 2024 $1,353 · 2025 $1,184
Food & beverage: $1,098Education: $87
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 3 | $158 |
| Merck Sharp & Dohme LLC | 6 | $157 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 8 | $151 |
| Regeneron Healthcare Solutions, Inc. | 3 | $132 |
| Verona Pharma, Inc. | 4 | $102 |
| ABBVIE INC. | 4 | $88 |
| Lilly USA, LLC | 3 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Novo Nordisk Inc | 2 | $38 |
Products named: WINREVAIR, DUPIXENT, EVENITY, Ohtuvayre, VRAYLAR, JARDIANCE, OFEV, GLASSIA.
Industry payments across CA — which companies pay providers there.
